Prognostic effects of SuPAR and Neopterin Levels on Patients with Lung Cancer

dc.contributor.author	Yalcin, Selim
dc.contributor.author	Demir, Mehmet Emin
dc.contributor.author	Ozturk, Reyhan
dc.contributor.author	Kilinc, Aytun Sadan
dc.contributor.author	Suer, Hatice
dc.contributor.author	Karahan, Irfan
dc.date.accessioned	2021-12-21T08:47:15Z
dc.date.available	2021-12-21T08:47:15Z
dc.date.issued	2020
dc.identifier.issn	0933-4807
dc.identifier.uri	https://doi.org/10.1515/pteridines-2020-0017
dc.identifier.uri	http://dspace.yeniyuzyil.edu.tr:8080/xmlui/handle/20.500.12629/2201
dc.description.abstract	Background: Two unique biomarkers, soluble form of the urokinase-type plasminogen activator receptor (suPAR) and neopterin, play a crucial role in inflammatory processes. This study aimed to reveal whether it is possible to utilize these biomarkers in pre
dc.language.iso	English
dc.publisher	Walter De Gruyter Gmbh
dc.rights	gold
dc.title	Prognostic effects of SuPAR and Neopterin Levels on Patients with Lung Cancer
dc.type	Article
dc.relation.journal	Pterıdınes
dc.identifier.issue	1
dc.identifier.startpage	136
dc.identifier.endpage	141
dc.identifier.volume	31
dc.identifier.doi	10.1515/pteridines-2020-0017
dc.relation.issue	1
dc.relation.volume	31

Files in this item

Files	Size	Format	View
There are no files associated with this item.